Risk management in dermatology: An analysis of data available from several British-based reporting systems

British Journal of Dermatology

Volumn 164, Issue 3, 2011, Pages 537-543

  Gawkrodger, D J ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT; RETINOID;

ARTICLE; CLINICAL PRACTICE; CRYOTHERAPY; DERMATOLOGY; DRUG MONITORING; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH SURVEY; HUMAN; INCIDENT REPORT; LASER; MEDICAL INFORMATION; NATIONAL HEALTH SERVICE; PATIENT SAFETY; PHOTOTHERAPY; PREGNANCY; PRIORITY JOURNAL; RISK MANAGEMENT; SKIN CANCER; SKIN SURGERY; UNITED KINGDOM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DERMATOLOGY; HUMANS; MEDICAL ERRORS; RISK MANAGEMENT; SAFETY; STATE MEDICINE;

EID: 79952366647     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10173.x     Document Type: Article

References (18)

1. European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). EMEA/CHMP/20857/2009. London, 19 February 2009. Available at: (last accessed 18 November 2010).
2. Crijns HJ, Straus SM, Gispen-de Wied CH, de Jong-van den Berg LT,. Compliance with Pregnancy Prevention Programs of isotretinoin in Europe: a systematic review. Br J Dermatol 2010; Aug 12 [Epub ahead of print].
3. Watson K, Hyrich K,. The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy. Musculoskeletal Care 2003; 1: 58-64.
4. National Institute for Health and Clinical Excellence. Etanercept and efalizumab for the treatment of adults with psoriasis. NICE Technology Appraisal Guidance 103, July 2006. Available at: (last accessed 18 November 2010).
5. Hollabaugh ES, Wagner RF Jr, Weedn VW, Smith EB,. Patient personal injury litigation against dermatology residency programs in the United States, 1964-1988. Implications for future risk-management programs in dermatology and dermatologic surgery. Arch Dermatol 1990; 126: 618-22. (Pubitemid 20157674)
6. National Patient Safety Agency. Our vision. NPSA, 2010. Available at: (last accessed 18 November 2010).
7. Drummond A, Kane D, Bilsland D,. Legal claims in Scottish National Health Service Dermatology Departments 1989-2001. Br J Dermatol 2003; 149: 111-14. (Pubitemid 36966519)
8. Trotter MJ, Bruecks AK,. Interpretation of skin biopsies by general pathologists: diagnostic discrepancy rate measured by blinded review. Arch Pathol Lab Med 2003; 127: 1489-92. (Pubitemid 37370398)
9. Troxel DB,. Pitfalls in the diagnosis of malignant melanoma: findings of a risk management panel study. Am J Surg Pathol 2003; 27: 1278-83. (Pubitemid 37040591)
10. Brochez L, Verhaeghe E, Grosshans E, et al. Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol 2002; 196: 459-66. (Pubitemid 34262859)
11. Read S, Hill H,. Dermatology's malpractice experience: clinical settings for risk management. J Am Acad Dermatol 2005; 53: 134-7. (Pubitemid 40826705)
12. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. Qual Saf Health Care 2004; 13: 145-51.
13. Cullen DJ, Bates DW, Small SD, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv 1995; 21: 541-8.
14. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285: 2114-20. (Pubitemid 32367829)
15. Knowles SR, Shapiro L, Shear NH,. Serious adverse reactions induced by minocycline. Arch Dermatol 1996; 132: 934-9.
16. Thielen AM, Kuenzli S, Saurat J-H,. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005; 211: 209-17. (Pubitemid 41415860)
17. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 2005; 293: 2131-40. (Pubitemid 40617066)
18. Brinker A, Kornegay C, Nourjah P,. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies. Arch Dermatol 2005; 141: 563-9. (Pubitemid 40656059)